Home・Akciju saraksts・Cytokinetics Inc

Cytokinetics Inc

Atvērts

SektorsVeselības aprūpe

77.12 -4.14

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

77.13

Max

79.99

Galvenie mērījumi
By Trading Economics
Ienākumi	-23M -206M
Pārdošana	1.6M 19M
EPS	-1.67
Peļņas marža	-1,064.485
Darbinieki	673
EBITDA	11M -169M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+36.53% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	2.7B 11B
Iepriekšējā atvēršanas cena	81.26
Iepriekšējā slēgšanas cena	77.12

Ziņu noskaņojums

By Acuity

50%

162 / 340 Rangs Healthcare

Cytokinetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. jūl. 18:46 UTC

Event

News

Social Media

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

2026. g. 29. jūl. 20:41 UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

2026. g. 28. jūl. 19:06 UTC

News

Cytokinetics shares are lower amid investor concerns over CEO Robert I. Blum's recent stock option exercise and sale, reported earlier today.

2026. g. 27. jūl. 19:56 UTC

Social Media

Cytokinetics Inc shares are lower, continuing a recent decline, amid social media discussions of a $103 price target and anticipated Myqorzo earnings in 2026.

2026. g. 24. jūl. 23:46 UTC

Cytokinetics Inc shares are lower in after-market hours, continuing recent weakness after three consecutive daily declines. No specific news was identified for the move.

2026. g. 22. jūl. 23:16 UTC

Cytokinetics Inc shares are lower in after-market hours amid broader market weakness, with no specific news identified to explain the decline.

2026. g. 21. jūl. 18:16 UTC

Cytokinetics Inc is trading higher, with no specific news identified. The stock has gained since Monday amid rising commodity prices, particularly copper and oil.

2026. g. 20. jūl. 19:22 UTC

News

Social Media

Cytokinetics shares are lower amid declines in the Biotechnology sector. Myqorzo revenue expectations exceed consensus, with a long-term projection of $1.67 billion by 2030.

Salīdzinājums

Cenas izmaiņa

Cytokinetics Inc Prognoze

Cenas mērķis

By TipRanks

36.53% augšup

Prognoze 12 mēnešiem

Vidējais 109.8 USD 36.53%

Augstākais 146 USD

Zemākais 83 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cytokinetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

16 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 16 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cytokinetics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

162 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.